Cyclin Proteolysis as a Retinoid Cancer Prevention Mechanism
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
The retinoids, natural and synthetic derivatives of vitamin A, are active in cancer therapy and prevention. Their biological effects are mediated through ligand‐dependent interactions with retinoid receptors that associate with specific co‐regulators. A better understanding of retinoid chemopreventive mechanisms is needed. Our prior work revealed that all‐trans‐retinoic acid (RA) prevented tobacco‐specific carcinogenic transformation of cultured human bronchial epithelial cells. RA signaled G1 arrest that permitted repair of genomic DNA damage caused by these carcinogens. RA triggered G1 arrest at least partly through proteasome‐dependent degradation of cyclin D1. Proteasomal inhibitors blocked RA‐mediated cyclin D1 degradation. To confirm that a specific proteolysis pathway was induced by RA‐treatment, a degradation assay was established using in vitro translated cyclin D1 and cellular extracts from RA‐treated or untreated human bronchial epithelial cells. Incubation of RA‐treated but not the control cellular extracts with in vitro translated cyclin D1 led to cyclin degradation. This degradation depended on the PEST domain of cyclin D1, implicating ubiquitination in this retinoid degradation. Retinoid receptor selective agonists demonstrated that retinoic acid receptor (RAR)β and retinoid X receptor (RXR) but not RARα‐ or RARγ‐dependent pathways signaled this cyclin degradation. Findings were extended to the NT2/D1 human embryonal carcinoma differentiation model where a similar pathway was activated by RA‐treatment. To determine whether G1 cyclins were involved directly in bronchial preneoplasia, immunohistochemical expression profiles for cyclins D1 and E were examined. Aberrant expression of these cyclins was frequent in bronchial preneoplasia. Taken together, these findings indicate that ubiquitin‐dependent proteolysis of G1 cyclins is a retinoid chemoprevention mechanism. Whether the retinoids represent the optimal agents to activate this pathway is the subject of ongoing work. These findings provide a rationale for combining the retinoids in chemoprevention trials with other agents that do not activate this proteolysis pathway. What is now known about the retinoids as cancer prevention agents will be reviewed. Emphasis is placed on retinoid effects on cell cycle progression at G1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A human retinoic acid receptor which belongs to the family of nuclear receptors
Petkovich, M., Brand, N. J., Krust, A., & Chambon, P. (1987) · Nature · doi:10.1038/330444a0 · Cited by 2,214
Identification of a receptor for the morphogen retinoic acid
Giguere, V., Ong, E. S., Segui, P., & Evans, R. M. (1987) · Nature · doi:10.1038/330624a0 · Cited by 1,965
9-cis retinoic acid is a high affinity ligand for the retinoid X receptor
Heyman, R. A., Mangelsdorf, D. J., Dyck, J. A., Stein, R. B., Eichele, G., Evans, R. M., & Thaller, C. (1992) · Cell · doi:10.1016/0092-8674(92)90479-v · Cited by 1,780
A unified nomenclature system for the nuclear receptor superfamily
(1999) · Cell · doi:10.1016/s0092-8674(00)80726-6 · Cited by 1,208
Meyskens, F. L., Surwit, E., Moon, T. E., Childers, J. M., Davis, J. R., Dorr, R. T., Johnson, C. S., & Alberts, D. S. (1994) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/86.7.539 · Cited by 263
Spinella, M. J., Freemantle, S. J., Sekula, D., Chang, J. H., Christie, A. J., & Dmitrovsky, E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.22013 · Cited by 165
Self-citation
Cited by
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
Hideshima, T., Mitsiades, C., Tonon, G., Richardson, P. G., & Anderson, K. C. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2189 · Cited by 932
“, by inducing its degradation through post-translational modifications (ubiquitylation and proteasomal degradation”
BackgroundAdvances in biology of multiple myeloma: clinical applications
Hideshima, T., Bergsagel, P. L., Kuehl, W. M., & Anderson, K. C. (2004) · Blood · doi:10.1182/blood-2004-01-0037 · Cited by 582
Cyclin D1: polymorphism, aberrant splicing and cancer risk
Knudsen, K. E., Diehl, J. A., Haiman, C. A., & Knudsen, E. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209371 · Cited by 363
Retinoids in cancer therapy and chemoprevention: Promise meets resistance
Freemantle, S. J., Spinella, M. J., & Dmitrovsky, E. (2003) · Oncogene · doi:10.1038/sj.onc.1206936 · Cited by 312
Self-citationLiu, L., & Gudas, L. J. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m509643200 · Cited by 181
Metadata
- Authors
- DRAGNEV, K. H., FREEMANTLE, S. J., SPINELLA, M. J., & DMITROVSKY, E.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2001-12
- Volume
- 952
- Issue
- 1
- Pages
- 13-22
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W2018514591
- Cited by
- 43
- References
- 6
- FWCI
- 1.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cyclin Proteolysis as a Retinoid Cancer Prevention Mechanism. https://app.cochat.ai/papers/10.1111/j.1749-6632.2001.tb02724.x
- The paper
- DRAGNEV, K. H., FREEMANTLE, S. J., SPINELLA, M. J., & DMITROVSKY, E. (2001). Cyclin Proteolysis as a Retinoid Cancer Prevention Mechanism. Annals of the New York Academy of Sciences. https://doi.org/10.1111/j.1749-6632.2001.tb02724.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.